These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 25812501)

  • 21. Effect of corticosteroids on phlebitis induced by intravenous infusion of antineoplastic agents in rabbits.
    Kohno E; Murase S; Matsuyama K; Okamura N
    Int J Med Sci; 2009 Aug; 6(5):218-23. PubMed ID: 19680474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Ruhlmann CH; Herrstedt J
    Expert Opin Drug Saf; 2011 May; 10(3):449-62. PubMed ID: 21417835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
    Gao HF; Liang Y; Zhou NN; Zhang DS; Wu HY
    Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.
    Navari RM
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):715-24. PubMed ID: 15485308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
    Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
    Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Carides G; Elmer M; Schmidt C; Evans JK; Horgan KJ
    J Clin Oncol; 2003 Nov; 21(22):4105-11. PubMed ID: 14559891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support.
    Paul B; Trovato JA; Thompson J; Badros AZ; Goloubeva O
    J Oncol Pharm Pract; 2010 Mar; 16(1):45-51. PubMed ID: 19525301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study.
    Albany C; Brames MJ; Fausel C; Johnson CS; Picus J; Einhorn LH
    J Clin Oncol; 2012 Nov; 30(32):3998-4003. PubMed ID: 22915652
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: A retrospective comparison.
    Tsuda T; Kyomori C; Mizukami T; Taniyama T; Izawa N; Horie Y; Hirakawa M; Ogura T; Nakajima TE; Tsugawa K; Boku N
    Mol Clin Oncol; 2016 Apr; 4(4):603-606. PubMed ID: 27073673
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Appropriate dosing of fosaprepitant for colon cancer patients].
    Aimono Y; Sakuyama K; Suzuki S; Nemoto M; Saito Y; Aoyama Y; Joko F; Maruyama T; Kamoshida T
    Gan To Kagaku Ryoho; 2015 Feb; 42(2):211-3. PubMed ID: 25743141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant.
    Lundberg JD; Crawford BS; Phillips G; Berger MJ; Wesolowski R
    Support Care Cancer; 2014 Jun; 22(6):1461-6. PubMed ID: 24402412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients.
    Loos WJ; de Wit R; Freedman SJ; Van Dyck K; Gambale JJ; Li S; Murphy GM; van Noort C; de Bruijn P; Verweij J
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):407-12. PubMed ID: 17051369
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review of the efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in a range of tumor types.
    Aapro MS; Schmoll HJ; Jahn F; Carides AD; Webb RT
    Cancer Treat Rev; 2013 Feb; 39(1):113-7. PubMed ID: 23062719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT(3) antagonists and dexamethasone.
    Oechsle K; Müller MR; Hartmann JT; Kanz L; Bokemeyer C
    Onkologie; 2006 Dec; 29(12):557-61. PubMed ID: 17202825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurokinin-1-receptor antagonists: a new approach in antiemetic therapy.
    Jordan K
    Onkologie; 2006 Feb; 29(1-2):39-43. PubMed ID: 16514255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects.
    Marbury TC; Jin B; Panebianco D; Murphy MG; Sun H; Evans JK; Han TH; Constanzer ML; Dru J; Shadle CR
    Anesth Analg; 2009 Aug; 109(2):418-25. PubMed ID: 19608812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of a Single 150-mg Intravenous Infusion of Fosaprepitant: Effects of Concentration and Infusion Time in Healthy Japanese Men.
    Azuma J; Fukase H
    Clin Pharmacol Drug Dev; 2013 Oct; 2(4):394-9. PubMed ID: 27121944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neutralization of prostaglandin E1 intravenous solution reduces infusion phlebitis.
    Fujita M; Hatori N; Shimizu M; Yoshizu H; Segawa D; Kimura T; Iizuka Y; Tanaka S
    Angiology; 2000 Sep; 51(9):719-23. PubMed ID: 10999612
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind study.
    Roila F; Ruggeri B; Ballatori E; Del Favero A; Tonato M
    J Clin Oncol; 2014 Jan; 32(2):101-6. PubMed ID: 24323030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.
    Warr DG; Grunberg SM; Gralla RJ; Hesketh PJ; Roila F; Wit Rd; Carides AD; Taylor A; Evans JK; Horgan KJ
    Eur J Cancer; 2005 Jun; 41(9):1278-85. PubMed ID: 15939263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.